The Drugs of Last Resort Are Failing: Resistance in One Hospital Superbug Has Nearly Doubled in a Decade, and the Caribbean Is Barely Counting
PAHO says resistance to last-line carbapenem antibiotics in Klebsiella pneumoniae rose from 15% to 26% across the Americas in a decade, but the figures rest on a minority of countries. The Caribbean’s surveillance gap is the real alarm.

There is a class of antibiotics doctors keep in reserve for the day nothing else works. Across the Americas, the Caribbean included, that reserve is running down, and most of the region’s governments could not tell you how fast.
The Pan American Health Organisation says resistance to carbapenems, the antibiotics often used when other treatments fail, has risen steadily over the past decade in two important bacteria. In Klebsiella pneumoniae it climbed from about 15 per cent in 2015 to 26 per cent in 2024. In Escherichia coli it rose from 3 to 5 per cent.
What the numbers mean
Put plainly, roughly one in four Klebsiella infections tested no longer responds to the drug of last resort. For a third bacterium, Acinetobacter baumannii, median resistance to carbapenems reached 77 per cent in 2024 in the countries that reported.
‘These data mean that hospital-acquired infections are becoming increasingly difficult to treat, posing greater risks to patients,’ said Pilar Ramón Pardo, chief of PAHO’s Special Programme on Antimicrobial Resistance. She called for stronger surveillance, infection prevention and access to new, effective antibiotics used appropriately.
This is not only a hospital problem. PAHO warns that resistance makes common community infections, such as urinary tract infections, harder to treat and more likely to end in complications and admission.
The scandal inside the statistics
Look at how many countries those figures rest on. The Klebsiella estimate draws on 15 countries. The E. coli figure on 13. The alarming Acinetobacter number comes from just seven. In a hemisphere of some three dozen states, most are either not measuring or not reporting, and PAHO itself says the data highlight the need to expand surveillance.
That is the part Caribbean health ministers should be made to answer for. You cannot manage what you do not count. How many of our public hospitals have a microbiology laboratory able to test routinely for resistance? How many report into the regional network? How many have a working infection control programme rather than a policy in a drawer? These are not expensive questions to answer, and the public has heard almost nothing.
Everyone has a part, but not an equal one
Antibiotic resistance has many authors. Patients who demand tablets for a cold, pharmacies that sell them without a prescription, and prescribers who hand them out to end a consultation all share the blame. So does agriculture: PAHO notes that antimicrobial use in animals can breed resistant bacteria that reach people through food, contact or the environment. ‘Resistant bacteria can circulate among animals, food, people, and the environment,’ said Manuel Sánchez Vázquez, director of its veterinary public health centre, urging countries to share information and strengthen surveillance.
But individuals cannot build laboratories or regulate farm drugs. Governments can. PAHO member states approved a new Plan of Action on Antimicrobial Resistance for 2027 to 2031 at their Directing Council in September. Approving a plan in a conference room is the easy part. Funding the labs, enforcing prescription rules and publishing each hospital’s resistance data is where it counts.
The findings were released for World Antimicrobial Resistance Awareness Week, November 18 to 24. Awareness is fine. What the Caribbean needs is a number for every hospital, a named official responsible for it, and the honesty to print it.



